Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current CML therapy: progress and dilemma.

R Hehlmann1

  • 1III Medizinische Klinik, Universitätsklinikum Mannheim der Universität Heidelberg, Wiesbadener Strasse 7-11, Mannheim D-68305, Germany.

Leukemia
|May 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Leukemia·2018
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Leukemia·2017
Same author

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

Leukemia·2016
Same author

Prof. Thomas Büchner (22 September 1934-5 August 2016)-A leading European hematologist and AML trialist.

Leukemia·2016
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
Same journal

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same journal

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Leukemia·2026
Same journal

PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.

Leukemia·2026
Same journal

Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.

Leukemia·2026
Same journal

Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis.

Leukemia·2026
See all related articles

Imatinib, a BCR-ABL tyrosine kinase inhibitor, offers rapid remissions for chronic myeloid leukemia (CML) that are comparable to hydroxyurea but with superior safety compared to interferon alpha.

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Chronic myeloid leukemia (CML) treatment has seen significant advancements.
  • The BCR-ABL tyrosine kinase inhibitor imatinib represents a breakthrough therapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of imatinib in treating CML.
  • To compare imatinib's performance against existing CML treatments like hydroxyurea and interferon alpha.

Main Methods:

  • Clinical assessment of remission rates.
  • Toxicological profiling of imatinib.
  • Comparative analysis with hydroxyurea and interferon alpha.

Main Results:

  • Imatinib induces remissions in CML as rapidly as hydroxyurea.

Related Experiment Videos

  • Cytogenetic remission rates with imatinib significantly surpass those of interferon alpha.
  • Imatinib exhibits a favorable toxicity profile, comparable to hydroxyurea and superior to interferon alpha.

    • Conclusions:

    • Imatinib is a highly effective and well-tolerated treatment for CML.
    • The targeted approach of imatinib may serve as a model for novel cancer therapies.